Works matching HER2/neu protein

Results: 90
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15

    P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer.

    Published in:
    Artificial Cells, Nanomedicine & Biotechnology, 2019, v. 47, n. 1, p. 664, doi. 10.1080/21691401.2019.1576702
    By:
    • Farzad, Niloofar;
    • Barati, Nastaran;
    • Momtazi-Borojeni, Amir Abbas;
    • Yazdani, Mona;
    • Arab, Atefeh;
    • Razazan, Atefeh;
    • Shariat, Sheida;
    • Mansourian, Mercedeh;
    • Abbasi, Azam;
    • Saberi, Zahra;
    • Badiee, Ali;
    • Jalali, Seyed Amir;
    • Jaafari, Mahmoud Reza
    Publication type:
    Article
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38

    Anti-HER2 Radioimmunotherapy.

    Published in:
    Breast Disease, 1999, v. 11, n. 1, p. 125
    By:
    • Brechbiel, Martin W.;
    • Waldmann, Thomas A.
    Publication type:
    Article
    39
    40
    41
    42

    Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancer.

    Published in:
    PLoS ONE, 2018, v. 13, n. 12, p. 1, doi. 10.1371/journal.pone.0208221
    By:
    • Polychronidou, Genovefa;
    • Kotoula, Vassiliki;
    • Manousou, Kyriaki;
    • Kostopoulos, Ioannis;
    • Karayannopoulou, Georgia;
    • Vrettou, Eleni;
    • Bobos, Mattheos;
    • Raptou, Georgia;
    • Efstratiou, Ioannis;
    • Dionysopoulos, Dimitrios;
    • Chatzopoulos, Kyriakos;
    • Lakis, Sotirios;
    • Chrisafi, Sofia;
    • Tsolakidis, Dimitrios;
    • Papanikolaou, Alexios;
    • Dombros, Nikolaos;
    • Fountzilas, George
    Publication type:
    Article
    43

    PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers.

    Published in:
    BMC Medical Genomics, 2012, v. 5, n. 1, p. 44, doi. 10.1186/1755-8794-5-44
    By:
    • Bastien, Roy RL;
    • Rodr¡guez-Lescure, µlvaro;
    • Ebbert, Mark TW;
    • Prat, Aleix;
    • Mun rriz, Blanca;
    • Rowe, Leslie;
    • Miller, Patricia;
    • Ruiz-Borrego, Manuel;
    • Anderson, Daniel;
    • Lyons, Bradley;
    • µlvarez, Isabel;
    • Dowell, Tracy;
    • Wall, David;
    • Segui, Miguel µngel;
    • Barley, Lee;
    • Boucher, Kenneth M;
    • Alba, Emilio;
    • Pappas, Lisa;
    • Davis, Carole A;
    • Aranda, Ignacio
    Publication type:
    Article
    44
    45
    46
    47
    48
    49
    50

    Evaluation of the HER2/neu‐derived peptide GP2 for use in a peptide‐based breast cancer vaccine trialThis article is a US Government work and, as such, is in the public domain in the United States of America.The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the Department of the Army or the Department of Defense.

    Published in:
    Cancer (0008543X), 2006, v. 106, n. 11, p. 2309
    By:
    • Elizabeth A. Mittendorf;
    • Catherine E. Storrer;
    • Rebecca J. Foley;
    • Katie Harris;
    • Yusuf Jama;
    • Craig D. Shriver;
    • Sathibalan Ponniah;
    • George E. Peoples
    Publication type:
    Article